688520 神州细胞
交易中 09-14 10:59:00
资讯
新帖
简况
神州细胞(688520.SH)股东拟合计减持不超0.94%股份
智通财经 · 09-13 15:46
神州细胞(688520.SH)股东拟合计减持不超0.94%股份
神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%
证券之星 · 08-31
神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%
神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显
证券之星 · 08-30
神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显
图解神州细胞中报：第二季度单季净利润同比下降94.80%
证券之星 · 08-29
图解神州细胞中报：第二季度单季净利润同比下降94.80%
每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准
证券之星 · 08-23
每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准
神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准
证券之星 · 08-19
神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准
神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升
证券之星 · 06-24
神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升
【机构调研记录】华夏基金调研神州细胞、瑞迈特等6只个股（附名单）
证券之星 · 06-01
【机构调研记录】华夏基金调研神州细胞、瑞迈特等6只个股（附名单）
【IPO速递】赴港！神州细胞（688520.SH）冲刺“A+H”，最大隐忧是什么？
IPO解码 · 05-27
【IPO速递】赴港！神州细胞（688520.SH）冲刺“A+H”，最大隐忧是什么？
神州细胞递表港交所：核心收入高度依赖单品，造血能力与出海野望“面临考验”
蓝鲸财经 · 05-25
神州细胞递表港交所：核心收入高度依赖单品，造血能力与出海野望“面临考验”
神州细胞（688520）披露向港交所递交H股发行及上市申请，5月25日股价下跌2.09%
证券之星 · 05-25
神州细胞（688520）披露向港交所递交H股发行及上市申请，5月25日股价下跌2.09%
神州细胞，递交香港IPO招股书，中信证券独家保荐
瑞恩资本 · 05-24
神州细胞，递交香港IPO招股书，中信证券独家保荐
每周股票复盘：神州细胞（688520）递交H股上市申请
证券之星 · 05-24
每周股票复盘：神州细胞（688520）递交H股上市申请
神州细胞冲刺港股：第一季营收3亿同比降38% 亏1.8亿
雷递网 · 05-23
神州细胞冲刺港股：第一季营收3亿同比降38% 亏1.8亿
新股消息 | 神州细胞(688520.SH)递表港交所
智通财经 · 05-23
新股消息 | 神州细胞(688520.SH)递表港交所
神州细胞最新公告：已向香港联交所递交H股发行及上市申请并刊发申请资料
证券之星 · 05-22
神州细胞最新公告：已向香港联交所递交H股发行及上市申请并刊发申请资料
神州细胞（688520）披露2025年年度股东会决议公告，5月13日股价下跌1.34%
证券之星 · 05-13
神州细胞（688520）披露2025年年度股东会决议公告，5月13日股价下跌1.34%
股市必读：神州细胞一季报 - 第一季度单季净利润同比下降375.51%
证券之星 · 05-06
股市必读：神州细胞一季报 - 第一季度单季净利润同比下降375.51%
每周股票复盘：神州细胞（688520）一季度净利降375.51%
证券之星 · 05-02
每周股票复盘：神州细胞（688520）一季度净利降375.51%
神州细胞(688520)3月31日股东户数1.35万户，较上期增加4.45%
证券之星 · 04-30
神州细胞(688520)3月31日股东户数1.35万户，较上期增加4.45%
暂无数据
公司概况
公司名称：
北京神州细胞生物技术集团股份公司
所属行业：
医药制造业
上市日期：
2020-06-22
主营业务：
北京神州细胞生物技术集团股份公司的主营业务是治疗性抗体、重组蛋白及疫苗的研发、生产与商业化。公司的主要产品是重组蛋白药物、抗体药物。
发行价格：
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":32.5,"timestamp":1789354740000,"preClose":32.41,"halted":0,"volume":1043867,"delay":0,"changeRate":0.0028,"floatShares":445000000,"shares":470000000,"eps":-1.9067,"marketStatus":"交易中","change":0.09,"latestTime":"09-14 10:59:00","open":32.05,"high":32.66,"low":31.5,"amount":33597500,"amplitude":0.0358,"askPrice":32.5,"askSize":3,"bidPrice":32.43,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-1.9067,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789356600000},"marketStatusCode":2,"adr":0,"adjPreClose":32.41,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":35.65,"lowLimit":29.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":470335714,"isCdr":false,"pbRate":-102.88,"roa":"--","roe":"--","epsLYR":-1.32,"committee":0.361702,"marketValue":15286000000,"turnoverRate":0.0023,"status":0,"floatMarketCap":14473000000},"requestUrl":"/m/hq/s/688520/tweets","defaultTab":"tweets","newsList":[{"id":"2667568970","title":"神州细胞(688520.SH)股东拟合计减持不超0.94%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2667568970","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667568970?lang=zh_cn&edition=full","pubTime":"2026-09-13 15:46","pubTimestamp":1789285585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神州细胞(688520.SH)发布公告，公司于近日收到股东暨员工持股平台神州安元、神州安恒、神州安成、神州安弘送达的《关于股份减持计划的告知函》，神州安元、神州安恒、神州安成、神州安弘因个人资金需求，计划通过集中竞价方式减持其持有的公司股份，合计不超过439.45万股(含本数)，占公司总股本不超过0.94%，减持期间为公告披露之日起15个交易日后的3个月内。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507122","title":"神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507122?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:03","pubTimestamp":1788170618,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，神州细胞报收于35.07元，较前一交易日下跌3.73%，最新总市值为164.95亿元。该股当日开盘36.23元，最高36.23元，最低34.85元，成交额达1.08亿元，换手率为0.69%。公司于近日披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为3,961,598,391.90元，较上年度末增长3.59%；归属于上市公司股东的净资产为633,391,841.97元，较上年度末增长393.78%。研发投入占营业收入的比例为58.89%，较上年同期增加18.98个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663484610","title":"神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663484610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663484610?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:17","pubTimestamp":1788041849,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期神州细胞发布2026年中报。截至本报告期末，公司营业总收入6.59亿元，同比下降32.16%，归母净利润-3.66亿元，同比下降982.86%。按单季度数据看，第二季度营业总收入3.36亿元，同比下降25.67%，第二季度归母净利润-1.9亿元，同比下降94.8%。本报告期神州细胞三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达37.06%。本文数据来源于神州细胞2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663180590","title":"图解神州细胞中报：第二季度单季净利润同比下降94.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663180590","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663180590?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:05","pubTimestamp":1787943921,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞2026年中报显示，上半年度公司主营收入6.59亿元，同比下降32.16%；归母净利润-3.66亿元，同比下降982.86%；扣非净利润-3.16亿元，同比下降775.87%；其中2026年第二季度，公司单季度主营收入3.36亿元，同比下降25.67%；单季度归母净利润-1.9亿元，同比下降94.8%；单季度扣非净利润-1.69亿元，同比下降182.74%；负债率83.84%，投资收益126.28万元，财务费用3571.32万元，毛利率90.31%。财报数据概要请见下图:本文数据来源于神州细胞2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661321122","title":"每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661321122","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661321122?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:31","pubTimestamp":1787423469,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，神州细胞报收于37.89元，较上周的39.4元下跌3.83%。本周，神州细胞8月20日盘中最高价报43.55元。SCTA02A为重组抗HBsAg单克隆抗体注射液，当前乙肝功能性治愈手段有限，临床需求较高。神州细胞控股子公司神州细胞工程有限公司获国家药品监督管理局批准，其自主研发的SCTB10注射液开展A型血友病I/II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660044429","title":"神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660044429","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660044429?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:22","pubTimestamp":1787134959,"startTime":"0","endTime":"0","summary":"神州细胞(688520.SH)公告称，公司控股子公司神州细胞工程收到国家药监局核准签发的《药物临床试验批准通知书》，同意自主研发产品SCTA02A注射液开展慢性乙型肝炎的临床试验。该产品是公司以功能性治愈慢性乙肝为目标设计的产品组合中首个获批临床的品种，本次获批开展I期临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900032307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645539860","title":"神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2645539860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645539860?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:11","pubTimestamp":1782285118,"startTime":"0","endTime":"0","summary":"神州细胞2025年经营现金流告负，流动负债缺口进一步扩大。截至2025年12月31日，安佳因已纳入国内20余个省级地区的省际联盟集中采购目录。神州细胞坦言，客户集中度相对较高，失去任何主要客户都可能对业务、经营业绩及财务状况造成不利影响。证券之星注意到，高毛利背后，神州细胞的盈亏反复。神州细胞表示，港股融资旨在打造国际化资本运作平台，拓宽全球资金渠道，增强长期资本实力。截至2025年末，神州细胞","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026062400022240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640598186","title":"【机构调研记录】华夏基金调研神州细胞、瑞迈特等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2640598186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640598186?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:02","pubTimestamp":1780272136,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月29日披露的机构调研信息，华夏基金近期对6家上市公司进行了调研，相关名单如下：1）神州细胞 调研纪要：公司2025年实现营业总收入15.60亿元，同比减少37.91%；归母净利润-5.65亿元。降价及销量下降。同时将公布ZG006在晚期神经内分泌癌、小细胞肺癌等适应症中的多项临床研究数据，部分入选胃肠道癌症专场口头报告。ZG006联合HS-20093治疗广泛期小细胞肺癌的临床试验已获批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100002545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239","BK0251","301367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638092658","title":"【IPO速递】赴港！神州细胞（688520.SH）冲刺“A+H”，最大隐忧是什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638092658","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638092658?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:07","pubTimestamp":1779869220,"startTime":"0","endTime":"0","summary":"近日，来自A股科创板的神州细胞正式向港交所递交招股书，拟在主板挂牌上市，由中信证券担任独家保荐人。值得一提的是，百济神州、恒瑞医药等创新药企已经完成两地布局，如果神州细胞此番成功上市，也将加入“A+H”大军。招股书显示，神州细胞于2020年6月登陆A股科创板，上市以来其股价起起落落，波动巨大，最新市值接近185亿元。神州细胞还有一点值得投资者注意，神州细胞登陆A股后，实控人并未稀释股权，反而主动加码。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2026-05-27/doc-inhzmayu7896728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","IPOS","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638553252","title":"神州细胞递表港交所：核心收入高度依赖单品，造血能力与出海野望“面临考验”","url":"https://stock-news.laohu8.com/highlight/detail?id=2638553252","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638553252?lang=zh_cn&edition=full","pubTime":"2026-05-25 21:41","pubTimestamp":1779716512,"startTime":"0","endTime":"0","summary":"目前来看，在去年以及今年一季度持续陷入大幅亏损后，神州细胞通过定增迅速缓解了现金流压力，短期内没有资金链断裂风险。在常年亏损之下，神州细胞财务压力较大，亟需通过多渠道进行融资。核心收入高度依赖单品翻阅上市申请文件，神州细胞拥有差异化的“硬资产”，且已沉淀出可验证的商业与制造能力。首先，核心收入高度依赖单品，虽然神州细胞目前有多个商业化产品，但目前为止，安佳因是其绝对收入支柱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779715232167185685","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IPOS","688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534612","title":"神州细胞（688520）披露向港交所递交H股发行及上市申请，5月25日股价下跌2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534612","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638534612?lang=zh_cn&edition=full","pubTime":"2026-05-25 18:03","pubTimestamp":1779703399,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，神州细胞报收于39.8元，较前一交易日下跌2.09%，最新总市值为187.19亿元。近日，神州细胞发布《关于向香港联交所递交H股发行及上市申请并刊发申请资料的公告》。公告显示，公司已于2026年5月22日向香港联合交易所有限公司递交发行H股并在主板上市的申请，并于同日在港交所网站刊登了申请资料。本次发行上市尚需获得中国证监会、香港证监会及港交所等监管机构批准，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500025601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HEXmain","BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637839309","title":"神州细胞，递交香港IPO招股书，中信证券独家保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2637839309","media":"瑞恩资本","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637839309?lang=zh_cn&edition=full","pubTime":"2026-05-24 21:50","pubTimestamp":1779630600,"startTime":"0","endTime":"0","summary":"2026年5月22日，来自北京的A股上市公司北京神州细胞生物技术集团股份公司SINOCELLTECH GROUP LIMITED向港交所递交招股书，拟在香港主板上市。神州细胞，于2020年06月22日在A股上市，截至2026年5月22日收市，其总市值约191亿元人民币。安贝珠上市后即被纳入国家医保药品目录。股东架构招股书显示，神州细胞在上市前的股东架构中，谢良志博士、李翰园女士夫妇，合计持股约70.86%，为控股股东。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-24/doc-inhyzkke4103994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0276","BK1147","LU1064131003.USD","LU1720050803.USD","LU1781817850.SGD","06030","LU1064130708.USD","BK0196","LU1997245094.SGD","BK0012","BK0183","BK0239","IPOS","LU1655091616.SGD","LU2289578879.USD","LU1997245177.USD","BK0188","688520","LU2495084118.USD","LU1997244956.HKD","LU1794554557.SGD","BK1564","LU0405327494.USD","LU2148510915.USD","BK1521","LU1255011170.USD","LU1328615791.USD","LU1580142542.USD","BK0028","600030","LU0405327148.USD","BK1516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637137653","title":"每周股票复盘：神州细胞（688520）递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637137653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637137653?lang=zh_cn&edition=full","pubTime":"2026-05-24 04:41","pubTimestamp":1779568869,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，神州细胞报收于40.65元，较上周的42.1元下跌3.44%。本周，神州细胞5月21日盘中最高价报43.43元。神州细胞当前最新总市值191.19亿元，在生物制品板块市值排名15/51，在两市A股市值排名1156/5206。本周关注点公司公告汇总：神州细胞已向港交所递交H股发行及上市申请。公司不会在境内媒体刊登该资料，相关信息可通过港交所网站查询。本次发行上市尚需获得中国证监会、香港证监会及港交所等监管机构批准，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637320565","title":"神州细胞冲刺港股：第一季营收3亿同比降38% 亏1.8亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2637320565","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637320565?lang=zh_cn&edition=full","pubTime":"2026-05-23 23:00","pubTimestamp":1779548422,"startTime":"0","endTime":"0","summary":"北京神州细胞生物技术集团股份公司（简称：“神州细胞”）日前递交招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260523/6391517400313277339139051.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260523/6391517400313277339139051.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33778/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688520","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637329912","title":"新股消息 | 神州细胞(688520.SH)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2637329912","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637329912?lang=zh_cn&edition=full","pubTime":"2026-05-23 15:06","pubTimestamp":1779519990,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所5月22日披露，北京神州细胞生物技术集团股份公司(688520.SH)向港交所主板递交上市申请书，中信证券为独家保荐人。据招股书，神州细胞是一家创新型生物制药公司，专注于治疗性抗体、重组蛋白及疫苗的研发、生产及商业化。自2002年成立以来，神州细胞一直致力于自主研发，建立了支持药物发现、临床开发及商业化的端到端开发平台。凭借集成技术平台，该公司已建立涵盖肿瘤、自身免疫、眼科、血友病及疫苗的产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688520","HEXmain","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348191","title":"神州细胞最新公告：已向香港联交所递交H股发行及上市申请并刊发申请资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348191","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637348191?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:50","pubTimestamp":1779461419,"startTime":"0","endTime":"0","summary":"神州细胞(688520.SH)公告称，公司已于5月22日向香港联交所递交了发行境外上市股份（H股）并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200045594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635173318","title":"神州细胞（688520）披露2025年年度股东会决议公告，5月13日股价下跌1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635173318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635173318?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:23","pubTimestamp":1778682196,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，神州细胞报收于42.77元，较前一交易日下跌1.34%，最新总市值为201.16亿元。神州细胞近日披露《2025年年度股东会决议公告》。公告显示，北京神州细胞生物技术集团股份公司于2026年5月13日召开2025年年度股东会，会议由董事会召集，董事长谢良志主持，采用现场与网络投票结合方式召开。出席会议股东共110人，代表有表决权股份总数的79.3346%。关联交易相关议案已按规定回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300045683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633827921","title":"股市必读：神州细胞一季报 - 第一季度单季净利润同比下降375.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633827921","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633827921?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:22","pubTimestamp":1778012532,"startTime":"0","endTime":"0","summary":"来自业绩披露要点：神州细胞2026年一季度归母净利润为-1.76亿元，同比下降375.51%。股本股东变化股东户数变动近日神州细胞披露，截至2026年3月31日公司股东户数为1.35万户，较12月31日增加575.0户，增幅为4.45%。业绩披露要点财务报告神州细胞2026年一季报显示，一季度公司主营收入3.23亿元，同比下降37.82%；归母净利润-1.76亿元，同比下降375.51%；扣非净利润-1.48亿元，同比下降725.6%；负债率81.6%，投资收益53.32万元，财务费用2177.92万元，毛利率89.57%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632973640","title":"每周股票复盘：神州细胞（688520）一季度净利降375.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632973640","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632973640?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:51","pubTimestamp":1777668669,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，神州细胞报收于41.18元，较上周的40.85元上涨0.81%。本周，神州细胞4月28日盘中最高价报42.59元。本周关注点业绩披露要点：神州细胞2026年一季报显示，归母净利润-1.76亿元，同比下降375.51%。股本股东变化股东户数变动截至2026年3月31日，神州细胞股东户数为1.35万户，较2025年12月31日增加575户，增幅4.45%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631690684","title":"神州细胞(688520)3月31日股东户数1.35万户，较上期增加4.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631690684","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631690684?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:35","pubTimestamp":1777541708,"startTime":"0","endTime":"0","summary":"证券之星消息，近日神州细胞披露，截至2026年3月31日公司股东户数为1.35万户，较12月31日增加575.0户，增幅为4.45%。在生物制品行业个股中，神州细胞股东户数低于行业平均水平，截至3月31日，生物制品行业平均股东户数为3.56万户。从股价来看，2025年12月31日至2026年3月31日，神州细胞区间跌幅为6.9%，在此期间股东户数增加575.0户，增幅为4.45%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000056561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789354745099,"stockEarnings":[{"period":"1week","weight":-0.0614},{"period":"1month","weight":-0.1586},{"period":"3month","weight":-0.0619},{"period":"6month","weight":-0.1774},{"period":"1year","weight":-0.4609},{"period":"ytd","weight":-0.2517}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11465人(较上一季度减少14.98%)","perCapita":"38843股","listingDate":"2020-06-22","address":"北京市大兴区北京经济技术开发区科创七街31号院5号楼307","registeredCapital":"47033万元","survey":" 北京神州细胞生物技术集团股份公司的主营业务是治疗性抗体、重组蛋白及疫苗的研发、生产与商业化。公司的主要产品是重组蛋白药物、抗体药物。","listedPrice":25.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}